Increased Expression of PD-L1 in Undifferentiated Non Keratinizing Squamous Cell Carcinoma Nasopharynx
DOI:
https://doi.org/10.36408/mhjcm.v8i2.579Keywords:
Nasopharyngeal carcinoma; PD-L1; prognostic factorAbstract
Increased Expression of PD-L1 in Undifferentiated Non Keratinizing Squamous Cell Carcinoma Nasopharynx
ABSTRACT
BACKGROUND: PD-L1 expressed by tumor cells in nasopharyngeal carcinoma (NPC) can be used by tumor cells to avoid the patient's immune system. This can affect prognosis such as age, gender, histopathological type, tumor stage and quality of life through immunosuppressive activity. PD-L1 expression is expected to be a biomarker for prognostic factor assessment and immunotherapy.
OBJECTIVE: To determine whether there is a relationship between the level of PD-L1 expression and prognostic factors in NPC.
METHODS: This is analytic observational study with a cross-sectional design. PD-L1 expression was examined immunohistochemically using 61 samples of paraffin block, which had been diagnosed as NPC in the Laboratory of Anatomical Pathology, Dr. Kariadi from January 2017 to June 2020. Patient clinical data were used as prognostic factors, namely age, gender, histopathological type, tumor stage and quality of life. Analysis was performed with the Chi-Square test to determine the relationship between the level of PD-L1 expression and prognostic factors.
RESULTS: There was a significant correlation between PD-L1expression in tumor cells and histopathological type (p=0.001). No significant correlation between PD-L1 expression and age (p=0.405), gender (p=0.241), tumor stage (p=0.928) and quality of life (p=0.103).
CONCLUSION: PD-L1 expression in this study cannot be used as a prognostic factor in NPC patients, although the histopathological type shows a significant relationship, so further research is needed with a larger sample and a longer period.
Keywords: Nasopharyngeal carcinoma; PD-L1; prognostic factor
Downloads
References
Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. http://globocan.iarc.fr/Default.aspx.
Adham M, Kurniawan AN, Muhtadi AI, et al. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer. 2012; 31: 185-196. doi: 10.5732/cjc.011.10328.
Prasetyo A. Karsinoma Nasofaring : Insidensi, faktor resiko, karsinogenesis dan diagnosis dini. Semarang. 2015; 22-35.
Peterson BF, Bell D, El-Mofty SK, et al. Nasopharyngeal carcinoma. In: El-Naggar AK, Chan JKC, Grandis JR, et al, editors. WHO Classification of head and neck tumours. 4th ed. Lyon: IARC; 2017: 65-70.
Qu Y, Wang D, Yang L, et al. Expression and clinical significance of programmed death ligand 1 in nasopharyngeal carcinoma. Mol Clin Oncol. 2018; 9(1): 75-81. doi: 10.3892/mco.2018.1633
Lin X, Gudgeon NH, Hui EP, et al. CD4 and CD8 T cell responses to tumour?associated Epstein?Barr virus antigens in nasopharyngeal carcinoma patients. Cancer Immunol Immunother. 2008; 57: 963?975. doi: 10.1007/s00262-007-0427-8.
Li X, Jiang Y, Zhao S, et al. High PD-L1 expression predicts metastasis in nasopharyngeal carcinoma. Astro. 2018; 102:E331. doi: https://doi.org/10.1016/j.ijrobp.2018.07.1018.
Iacovelli N A, Bossi P, Fallai C, et al. Emerging prognostic factors in Nasopharyngeal carcinoma. J Nasopharyng Carcinoma. 2014; 1(8): e8. doi: 10.15383/jnpc.8
Zhang J, Fang W, Qin T, et al. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. Med Oncol. 2015; 32: 86. doi: 10.1007/s12032-015-0501-6
Li YF, Ding JW, Liao LM, Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma. Mol Clin Oncol. 2017 Sep;7(3): 378-382. doi: 10.3892/mco.2017.1318.
Zheng L, Cao C, Cheng G, et al. Cytomembranic PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma. Onco Targets Ther. 2017 Nov 16; 10: 5483-5487. doi: 10.2147/OTT.S152007.
Gholami A, Jahromi LM, Zarei E, et al. Application of WHOQOL-BREF in Measuring Quality of Life in Health-Care Staff. Int J Prev Med. 2013 Jul; 4(7): 809–817. PMCID: PMC3775221.
Fang FM, Tsai WL, Chien CY, et al. Pretreatment quality of life as a predictor of distant metastasis and survival for patients with nasopharyngeal carcinoma. J Clin Oncol. 2010 Oct 1; 28(28): 4384-9. doi: 10.1200/JCO.2010.28.8324
Chang AMV, Chiosea SI, Altma A, et al. Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein–Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines. Head and Neck Pathol (2017) 11: 203–211. doi: 10.1007/s12105-016-0765-y.
Zhao L, Liao X, Hong G, et al. Mismatch repair status and high expression of PD-L1 in nasopharyngeal carcinoma. Cancer Manag Res. 2019; 11: 1631–1640. doi: 10.2147/CMAR.S193878.
García A, Recondo G, Greco M, et al. Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma. Heliyon. 2020 Jun; 6(6): e04117. https://doi.org/10.1016/j.heliyon.2020.e04117.
Kwong FNK, Laggner U, McKinney O, et al. Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas. Histopathology 2018 May;72(6):1024-1032. doi: 10.1111/his.13466. Epub 2018 Mar 5.
Goto Y. Tumor Mutation Burden: Is It Ready for the Clinic?. J Clin Oncol. 2018 Oct 20;36(30):2978-2979. doi: 10.1200/JCO.2018.79.3398.
Yarchoan M, Albacker LA, Hopkins AC. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight. 2019 Mar 21; 4(6): e126908. doi: 10.1172/jci.insight.126908.
Ali SM, Yao M, Yao J. Comprehensive Genomic Profiling of Different Subtypes of Nasopharyngeal Carcinoma Reveals Similarities and Differences to Guide Targeted Therapy. Cancer. 2017 Sep 15;123(18):3628-3637. doi: 10.1002/cncr.30781.
Xie SH, Yu ITS, Tse LA, et al. Sex difference in the incidence of nasopharyngeal carcinoma in Hong Kong 1983-2008: suggestion oaf a potential protective role of oestrogen. Eur J Cancer. 2013 Jan;49(1):150-5. doi: 10.1016/j.ejca.2012.07.004. Epub 2012 Aug 11.
Feng R, Chang ET, Liu Z, et al. Reproductive History and Risk of Nasopharyngeal Carcinoma: A Population-Based Case–Control Study in Southern China. Oral Oncol. 2019 Jan; 88: 102–108. doi: 10.1016/j.oraloncology.2018.11.025.
Bray F, Haugen M, Tron A, Moger TA, et al. Age-Incidence Curves of Nasopharyngeal Carcinoma Worldwide: Bimodality in Low-Risk Populations and Aetiologic Implications. American Association for Cancer Research. September 2008. Volume 17, Issue 9. DOI: 10.1158/1055-9965.EPI-08-0461 Published September 2008.
Yu W, Hua Y, Qiu H, et al. PD-L1 promotes tumor growth and progression by activating WIP and ?-catenin signaling pathways and predicts poor prognosis in lung cancer. Cell Death Dis 11, 506 (2020). https://doi.org/10.1038/s41419-020-2701-z.
Chen J, Jiang CC, Jin L3. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Annals of Oncology 27: 409–416, 2016. doi:10.1093/annonc/mdv615.
Chen L, Gibbons DL, Goswami S, et al. Metastasis is regulated via microRNA-200/ ZEB1 axis control of tumour cell P1D-L1 expression and intratumoral immunosuppression. Nat Commun 2014; 5(article 5241): 1–12. https://doi.org/10.1038/ncomms6241.
Additional Files
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2021 Medica Hospitalia : Journal of Clinical Medicine
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.
